Show simple item record

dc.contributor.authorChapagain, Ananda
dc.date.accessioned2016-05-27T10:37:20Z
dc.date.available2016-05-27T10:37:20Z
dc.date.issued2016-03-17
dc.date.submitted2016-05-27T11:33:04.600Z
dc.identifier.citationChapagain, A. 2016. The role of Hepatic 11-β hydroxysteroid dehydrogenase Type 1 in Uraemia-induced Insulin Resistance. Queen Mary University of Londonen_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/12581
dc.description.abstractInsulin resistance and associated metabolic sequelae are common in Chronic Kidney Disease (CKD) and are positively and independently associated with increased cardiovascular mortality. However, the pathogenesis has yet to be fully elucidated. 11β-Hydroxysteroid Dehydrogenase type 1 (11β-HSD1) catalyses intracellular regeneration of active glucocorticoids, promoting insulin resistance in liver and other metabolic tissues. Using data from two experimental rat models of CKD (subtotal nephrectomy and adenine diet) which show early insulin resistance, we found that 11β-HSD1 mRNA and protein increase in hepatic and adipose tissue, together with increased hepatic 11β-HSD1 activity. This was associated with intrahepatic but not circulating glucocorticoid excess, and increased hepatic gluconeogenesis and lipogenesis. Oral administration of the 11β-HSD inhibitor carbenoxolone to uraemic rats for 2 weeks improved glucose tolerance and insulin sensitivity, improved insulin signalling, and reduced hepatic expression of gluconeogenic and lipogenic genes. Furthermore, 11β-HSD1−/− mice and rats treated with a specific 11β-HSD1 inhibitor (UE2316) were protected from metabolic disturbances despite similar renal dysfunction following adenine-induced experimental uraemia. Therefore, we demonstrate that elevated hepatic 11β-HSD1 is an important contributor to early insulin resistance and dyslipidaemia in uraemia. Specific 11β-HSD1 inhibitors potentially represent a novel therapeutic approach for management of insulin resistance in patients with CKD.
dc.language.isoenen_US
dc.publisherQueen Mary University of Londonen_US
dc.subjectchronic kidney disease,en_US
dc.subjectUraemiaen_US
dc.subjectInsulin resistanceen_US
dc.subjectrenal dysfunctionen_US
dc.titleThe role of Hepatic 11-β hydroxysteroid dehydrogenase Type 1 in Uraemia-induced Insulin Resistance.en_US
dc.typeThesisen_US
dc.rights.holderThe copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Theses [2785]
    Theses Awarded by Queen Mary University of London

Show simple item record